Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional)

The summary for the Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional): This Funding Opportunity Announcement (FOA) supports planning, design and initial pilots for locally relevant and catalytic research on non-communicable diseases (NCDs) or injury in low and middle-income countries (LMICs). Research addressing multiple NCDs and their risk factors and research addressing NCDs as comorbidities for/with infectious diseases including HIV/AIDS is encouraged. Scientists in the United States (U.S.) or upper middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Income categories used are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. Pilot activities and research are expected to inform the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address NCDs and injury throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.
Federal Grant Title: Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Environment Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-19-059
Type of Funding: Grant
CFDA Numbers: 93.113, 93.213, 93.242, 93.307, 93.313, 93.321, 93.867
CFDA Descriptions: Information not provided
Current Application Deadline: December 13th, 2019
Original Application Deadline: December 13th, 2019
Posted Date: November 7th, 2018
Creation Date: November 7th, 2018
Archive Date: January 18th, 2020
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: November 7th, 2018
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See FOA for full eligibility details.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-19-059.html
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Scree...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com